Orbicular’s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic® (Semaglutide Injection), supported by OneSource as CDMO partner
2026-OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) today announced that its partner Orbicular Pharmaceutical Technologies (“Orbicular”), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S.…